We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Tiny Shunt Device Alleviates Heart Failure Symptoms

By HospiMedica International staff writers
Posted on 04 Sep 2023

Heart failure ranks as the leading cause of hospital admissions worldwide. This chronic ailment occurs when the heart muscle functions inefficiently. Among heart failure cases, about half fall under heart failure with preserved ejection fraction (HFpEF), characterized by stiffening of the heart muscle, impairing proper relaxation and filling. This progression often leads to symptoms like shortness of breath, fatigue, swelling in the legs and ankles, and exercise challenges. Now, a novel investigational device relieves pressure in the left side of the heart, thereby reducing symptoms of heart failure such as shortness of breath.

Atrial fibrillation and a leaky mitral valve are frequently observed in heart failure patients. When conventional approaches like medications and lifestyle adjustments fall short, corrective procedures may be necessary that require the interatrial septum for the catheter’s entry. The Apture transcatheter shunt system from Edwards Lifesciences (Irvine, CA, USA) offers an innovative solution to offload the left side of the heart while preserving the septum for future interventions. During the procedure, doctors insert a catheter through a neck vein, providing access to the heart. The tiny shunt device is implanted between the coronary sinus vein and the left atrium. This placement maintains the interatrial septum, the wall dividing the upper chambers of the heart. Following the successful implantation of the device in an early feasibility study in April 2022, researchers have now enrolled the world's first patient in a clinical trial to assess its effectiveness. The trial, known as ALT-FLOW II, is a randomized, double-blind study that will involve a total of 100 patients across 30 investigational sites.


Image: The novel investigational device is designed to relieve pressure in the left side of heart (Photo courtesy of Freepik)
Image: The novel investigational device is designed to relieve pressure in the left side of heart (Photo courtesy of Freepik)

Related Links:
Edwards Lifesciences


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Ultra Low Floor Level Bed
Solite Pro

Latest Critical Care News

Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients

Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot

One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes